Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Change in Receivables: 2015-2024

Historic Change in Receivables for Cytokinetics (CYTK) over the last 10 years, with Dec 2024 value amounting to $15.4 million.

  • Cytokinetics' Change in Receivables fell 2805.74% to -$6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 169.36%. This contributed to the annual value of $15.4 million for FY2024, which is 1252.73% up from last year.
  • According to the latest figures from FY2024, Cytokinetics' Change in Receivables is $15.4 million, which was up 1,252.73% from $1.1 million recorded in FY2023.
  • Cytokinetics' Change in Receivables' 5-year high stood at $47.4 million during FY2021, with a 5-year trough of -$56.7 million in FY2022.
  • In the last 3 years, Cytokinetics' Change in Receivables had a median value of $1.1 million in 2023 and averaged -$13.4 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first soared by 6,479.41% in 2021, then crashed by 219.56% in 2022.
  • Over the past 5 years, Cytokinetics' Change in Receivables (Yearly) stood at -$743,000 in 2020, then surged by 6,479.41% to $47.4 million in 2021, then plummeted by 219.56% to -$56.7 million in 2022, then skyrocketed by 102.00% to $1.1 million in 2023, then soared by 1,252.73% to $15.4 million in 2024.